Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JAZZNASDAQ:MDGLNASDAQ:ROIVNASDAQ:TRIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJAZZJazz Pharmaceuticals$110.04-8.9%$132.27$99.06▼$148.06$6.68B0.44754,628 shs2.17 million shsMDGLMadrigal Pharmaceuticals$314.39-3.9%$333.68$189.00▼$377.46$6.94B-0.68388,636 shs343,494 shsROIVRoivant Sciences$9.46-5.5%$10.62$9.42▼$13.06$6.75B1.265.32 million shs10.14 million shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJAZZJazz Pharmaceuticals-8.92%-10.48%-21.53%-8.73%-5.88%MDGLMadrigal Pharmaceuticals-3.89%-4.11%-9.47%-1.66%+28.20%ROIVRoivant Sciences-5.49%-8.86%-11.59%-19.08%-17.81%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJAZZJazz Pharmaceuticals4.815 of 5 stars4.51.00.04.03.52.53.1MDGLMadrigal Pharmaceuticals3.3562 of 5 stars2.40.00.04.62.64.20.6ROIVRoivant Sciences2.2633 of 5 stars3.51.00.00.03.53.30.0TRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJAZZJazz Pharmaceuticals 2.93Moderate Buy$187.7170.59% UpsideMDGLMadrigal Pharmaceuticals 2.80Moderate Buy$378.4420.37% UpsideROIVRoivant Sciences 3.00Buy$17.5084.99% UpsideTRILTrillium Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRIL, JAZZ, MDGL, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/10/2025JAZZJazz PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$200.00 ➝ $217.003/7/2025JAZZJazz PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$175.00 ➝ $183.003/7/2025JAZZJazz PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$145.00 ➝ $179.003/6/2025JAZZJazz PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$220.00 ➝ $230.003/5/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$210.00 ➝ $210.003/4/2025ROIVRoivant SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/27/2025JAZZJazz PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$190.00 ➝ $200.002/27/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$236.00 ➝ $422.002/27/2025MDGLMadrigal PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$378.00 ➝ $469.002/27/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$400.00 ➝ $405.002/26/2025JAZZJazz PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$140.00 ➝ $150.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJAZZJazz Pharmaceuticals$4.07B1.64$22.41 per share4.91$59.36 per share1.85MDGLMadrigal Pharmaceuticals$180.13M38.54N/AN/A$20.53 per share15.31ROIVRoivant Sciences$122.59M55.07N/AN/A$7.76 per share1.22TRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJAZZJazz Pharmaceuticals$414.83M$8.7915.505.881.0411.60%29.30%9.72%4/29/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$373.63M-$22.11N/AN/AN/AN/A-71.78%-53.25%5/6/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)TRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/ALatest TRIL, JAZZ, MDGL, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2025Q4 2024MDGLMadrigal Pharmaceuticals-$4.32-$2.71+$1.61-$2.71$97.81 million$103.32 million2/10/2025Q3 2025ROIVRoivant Sciences-$0.24-$0.20+$0.04$0.23$4.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJAZZJazz Pharmaceuticals1.464.263.74MDGLMadrigal Pharmaceuticals0.155.985.93ROIVRoivant SciencesN/A37.9137.91TRILTrillium TherapeuticsN/A19.8219.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJAZZJazz Pharmaceuticals89.14%MDGLMadrigal Pharmaceuticals98.50%ROIVRoivant Sciences64.76%TRILTrillium Therapeutics87.15%Insider OwnershipCompanyInsider OwnershipJAZZJazz Pharmaceuticals4.20%MDGLMadrigal Pharmaceuticals22.80%ROIVRoivant Sciences7.90%TRILTrillium Therapeutics9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJAZZJazz Pharmaceuticals3,20060.73 million57.92 millionOptionableMDGLMadrigal Pharmaceuticals9022.08 million16.84 millionOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableTRIL, JAZZ, MDGL, and ROIV HeadlinesRecent News About These CompaniesTTI Consumer Power Tools, Inc. is Seeking an IP ParalegalSeptember 26, 2024 | ipwatchdog.comAdvances in Drug Discovery & Development 2024September 8, 2024 | technologynetworks.comWhen You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) StockJuly 30, 2024 | finance.yahoo.comGoogle Cloud unveils the Trillium TPU, its most powerful AI processor so farMay 14, 2024 | siliconangle.comCachet Bicycle shakes off COVIDFebruary 25, 2024 | baytoday.caRejuvenate your look with a trip to Fourth Avenue Medical AestheticsJanuary 30, 2024 | chch.comTTI apprehends motorists for illegal removal of clamps, hunt for four others underwayJanuary 30, 2024 | bulawayo24.comBridgeBio raises $1.25bn, and other biotech financingsJanuary 19, 2024 | pharmaphorum.comRatio Therapeutics Raises $50M in Series B FinancingJanuary 17, 2024 | precisionmedicineonline.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 10, 2023 | businesswire.comMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | benzinga.comThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodJuly 31, 2023 | uk.finance.yahoo.comRatio Therapeutics unveils new research and development facilityMay 15, 2023 | biopharma-reporter.comWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'April 26, 2023 | msn.comLeukemia Therapeutics Global Market Report 2023April 4, 2023 | uk.finance.yahoo.comRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckMarch 28, 2023 | finance.yahoo.comTrillium House, an affordable housing project in Warrenton, close to completionJanuary 10, 2023 | dailyastorian.comFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular CarcinomaOctober 19, 2022 | nz.finance.yahoo.comCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentSeptember 14, 2022 | seekingalpha.comZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of DirectorsSeptember 12, 2022 | nz.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyPrice Targets Show These 3 Stocks Near the $1 Trillion MarkBy Leo Miller | March 27, 2025View Price Targets Show These 3 Stocks Near the $1 Trillion MarkBoeing Gets $50B in March Orders—Is BA Stock a Buy Now?By Jea Yu | April 4, 2025View Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?Charles Schwab Stock: Trading Up in a Down MarketBy Jea Yu | April 4, 2025View Charles Schwab Stock: Trading Up in a Down MarketTRIL, JAZZ, MDGL, and ROIV Company DescriptionsJazz Pharmaceuticals NASDAQ:JAZZ$110.04 -10.78 (-8.92%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$112.05 +2.01 (+1.83%) As of 04/4/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Madrigal Pharmaceuticals NASDAQ:MDGL$314.39 -12.71 (-3.89%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$299.69 -14.70 (-4.68%) As of 04/4/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Roivant Sciences NASDAQ:ROIV$9.46 -0.55 (-5.49%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$9.46 -0.01 (-0.05%) As of 04/4/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Trillium Therapeutics NASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
